Investigators at the Imperial College London developed a liver-on-a-chip platform capable of hosting the hepatitis B virus. The system, which captured all stages in the hepatitis B virus life cycle, could reduce the costs of drug development, researchers wrote in the journal Nature Communications.
A study in The Lancet Infectious Diseases found the addition of primaquine and methylene blue to antimalarial regimens blocked human-to-mosquito transmission. The midstage randomized study tested four regimens in 80 participants.
Baylor Scott & White Health in Texas has begun a kidney transplant program focused on the needs of Latino communities. The program will offer bilingual education and attempt to increase living donations.
Agios Pharmaceuticals' new-drug application for ivosidenib, which is being developed as a treatment for patients with isocitrate dehydrogenase 1 mutation-positive relapsed/refractory acute myeloid leukemia, was accepted for priority review by the FDA. The PDUFA date for the drug is Aug. 21.
Researchers from the Institut Pasteur-Paris found that gene variations that influence susceptibility to dengue fever and dengue shock syndrome differ among world populations, according to a study in the journal PLOS Neglected Tropical Diseases. "The particular genetic risk conferred by these genes indicates that Southeast and Northeast Asians are highly susceptible to both phenotypes, while Africans are best protected against DSS and Europeans best protected against DF, but the most susceptible to DSS," the study team wrote.
The Department of Veterans Affairs has awarded a five-year contract to Magnolia Medical Technologies to supply the Steripath Initial Specimen Diversion Device for blood culture collection.
Banyan Biomarkers' Brain Trauma Indicator is the first blood test to receive FDA approval to screen for a certain type of brain damage that is usually only detectable with CT scans. The test assesses levels of two proteins, UCH-L1 and GFAP, and it could reduce the need for unnecessary neuroimaging tests and radiation exposure.
Astellas Pharma will pay $102.5 million upfront to acquire Seattle-based Universal Cells, the firm that developed the Universal Donor Cell technology, which produces cell therapy products that do not need human leukocyte antigen matching. The deal will also let Japan-based Astellas apply the technology to other diseases.
Researchers analyzed data for 498 leukemia patients with a median age of 6 for three influenza seasons from 2010 to 2013 and found that rates of influenza and influenza-like illness were the same with and without influenza vaccination. Hand hygiene and additional precautionary measures should be taken for leukemia patients, according to the study in the Journal of Pediatrics.
Emory University School of Medicine scientists have created a miniature model to simulate a mechanical injury to a small blood vessel and track the hemostatic process at the single-cell level. The microfluidics-based system allows researchers to observe the three mechanisms involved in bleeding at work together: blood vessel narrowing, platelet activity and clotting factor activity.